Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation

蒽环类抗癌化疗结果的改善对国家有明显的好处。肿瘤局部治疗预计将改善反应，减少副作用和改善生活质量，而合理选择药物组合预计将能够治疗以前对蒽环类抗生素耐药的肿瘤。随着澳大利亚人口的老龄化，预计癌症的发病率将急剧上升-改善治疗结果和更好地使用化疗药物将对国家产生明显的好处。新的肿瘤靶向药物的开发是澳大利亚和美国联合知识产权的主题，提供潜在的经济利益。

Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Australia the incidence of cancer is predicted to rise dramatically - improved treatment outcomes and better use of chemotherapeutics will be of obvious national benefit. The development of new tumour-targeted agents is the subject of joint Intellectual Property between Australia and the USA, offering potential economic benefit.